Sp302
HEPATIC PATHOLOGY FOR THE GI PROVIDER
Date
May 18, 2024
Tracks
Related Products
Career Planning for APPs (Hep Associations Committee)
ADDICTION TREATMENT AND HARM REDUCTION IN VIRAL HEPATITIS
PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY
BACKGROUND: Approximately 40% of primary biliary cholangitis (PBC) patients exhibit poor response to ursodeoxycholic acid (UDCA) and prognosis, referred to as refractory PBC. There is an urgent need to explore new treatment approaches for this patient population…